| Outcome Measures: |
Primary: Part 1: Percentage of Participants With Any Adverse Event (AE), An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants that experienced an AE was summarized., Up to 164 days|Part 2: Percentage of Participants With Any AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE was summarized., Up to 118 days|Part 1: Percentage of Participants With Any Serious Adverse Event, A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized., Up to 164 days|Part 2: Percentage of Participants With Any SAE, An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants who experienced an SAE was summarized., Up to 118 days|Part 1: Percentage of Participants With a Systemic AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath., Up to 164 days|Part 2: Percentage of Participants With a Systemic AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited systemic AEs assessed included but not limited to fever, vital sign (VS) changes (tachycardia/hypotension), pruritis, urticarial (hives), lip swelling, angioedema, bronchospasm, stridor, hoarseness, and shortness of breath., Up to 118 days|Part 1: Percentage of Participants With an Injection-Site AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling., Up to 164 days|Part 2: Percentage of Participants With an Injection-Site AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The solicited injection-site AEs assessed were pain, tenderness, erythema/redness, and induration/swelling., Up to 118 days|Part 1: Percentage of Participants Discontinuing the Study Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that discontinued the study due to an AE was summarized., Up to 164 days|Part 2: Percentage of Participants Discontinuing Study Drug Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants that had study drug discontinued regardless of study completion status was summarized., Up to 4 weeks | Secondary: Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From 0 to Infinity (AUC0-inf), Plasma samples were collected at pre-specified time points post-dose and AUC0-inf was assessed., Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose, then Days 12, 15, 22, 29, 60, 90, 120, 150|Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168), Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed., Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose|Part 1: Maximum Observed Plasma Concentration (Cmax) of MK-2060, Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed., Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose, then Days 12, 15, 22, 29, 60, 90, 120, 150|Part 1: Plasma Concentration of MK-2060 at 168 Hours (C168), Plasma samples were collected at 168 hours post-dose and C168 was assessed., 168 hours post dose|Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060, Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed., Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose|Part 1: Plasma Elimination Terminal Half-life (t ½) of MK-2060, Plasma samples was collected at pre-specified time points post-dose and t ½ was assessed., Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose|Part 1: Plasma Clearance (CL) of MK-2060, Plasma samples were collected at pre-specified time points post-dose and CL was assessed., Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose|Part 1: Plasma Volume of Distribution (Vz) of MK-2060, Plasma samples were collected at pre-specified time points post-dose and Vz was assessed., Predose Day 1 and 1, 12, 24, 48, 52, 96, 168 hours postdose|Part 2: AUC0-168 of MK-2060, Plasma samples were collected at pre-specified time points post-dose and AUC0-168 hours was assessed., Up to 168 hours on Day 1 and Day 22|Part 2: Cmax of MK-2060, Plasma samples were collected at pre-specified time points post-dose and Cmax was assessed., Day 1 and Day 22|Part 2: C168 of MK-2060, Plasma samples were collected at 168 hours post-dose and C168 was assessed., 168 hours post dose on Days 1 and 22|Part 2: Tmax of MK-2060, Plasma samples were collected at pre-specified time points post-dose and Tmax was assessed., Day 1 and Day 22|Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060: Part 1, Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported., Baseline and 168 hours post-dose (Day 8)|Fold Change From Baseline in aPTT of MK-2060: Part 2, Plasma samples were collected at pre-specified time points post-dose and aPTT values were assessed. The fold change (Day 8/Baseline) at Day 8 was reported., Baseline and Day 8
|
